Literature DB >> 30965373

Association of Surgical Resection, Disability, and Survival in Patients with Glioblastoma.

Yahya Ahmadipour1, Monika Kaur1, Daniela Pierscianek1, Oliver Gembruch1, Marvin Darkwah Oppong1, Oliver Mueller1, Ramazan Jabbarli1, Martin Glas2, Ulrich Sure1, Nicolai El Hindy1.   

Abstract

OBJECTIVE: Extent of resection (EOR) and Karnofsky Performance Status (KPS) are at odds in glioblastoma (GBM) surgery, that is, the anticipated postoperative disability limits the EOR. This study analyzes the correlation of different surgical modalities with the resulting physical status and survival of patients with GBM.
METHODS: A total of 565 patients with primary GBM were operated on in a single institution between 2006 and 2014. Possible surgical modalities comprised supratotal resection (SLR), gross total resection (GTR; ≥ 95% by volume), tumor debulking (TDB; ≤ 95% by volume), and stereotactic biopsy (SB). Pre- and postoperative KPS before and up to 4 weeks after surgery as well as overall survival (OS) rate were determined retrospectively. Hazard ratio (HR) and 95% confidence intervals were calculated using a Cox proportional hazards model.
RESULTS: Median postoperative KPS was ≥ 70, irrespective of surgical modality. Mean OS was 12.5 months. Multivariate analysis revealed age ≥ 70 years (HR: 1.93), preoperative KPS < 70 (HR: 2.15), and unmethylation in MGMT promoter (HR: 1.27) as independent factors for worse OS. Regarding surgical modality, SB was associated with the worst survival (HR: 2.3) followed by TDB (HR: 1.36). SLR was inferior to GTR (HR: 1.27).
CONCLUSION: Higher EOR in patients with GBM does not seem inevitably correlated with increasing functional impairment, but better survival, provided there is a balanced preoperative indication. Nevertheless, SLR does not seem to be superior to GTR. Whenever possible, maximal safe resection should be considered in patients with GBM, even if an EOR ≥ 95% is not possible. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2019        PMID: 30965373     DOI: 10.1055/s-0039-1685170

Source DB:  PubMed          Journal:  J Neurol Surg A Cent Eur Neurosurg        ISSN: 2193-6315            Impact factor:   1.268


  4 in total

1.  Impact of initial midline shift in glioblastoma on survival.

Authors:  Johannes Wach; Motaz Hamed; Patrick Schuss; Erdem Güresir; Ulrich Herrlinger; Hartmut Vatter; Matthias Schneider
Journal:  Neurosurg Rev       Date:  2020-06-04       Impact factor: 3.042

2.  Association of Neurological Impairment on the Relative Benefit of Maximal Extent of Resection in Chemoradiation-Treated Newly Diagnosed Isocitrate Dehydrogenase Wild-Type Glioblastoma.

Authors:  Alexander A Aabedi; Jacob S Young; Yalan Zhang; Simon Ammanuel; Ramin A Morshed; Cecilia Dalle Ore; Desmond Brown; Joanna J Phillips; Nancy Ann Oberheim Bush; Jennie W Taylor; Nicholas Butowski; Jennifer Clarke; Susan M Chang; Manish Aghi; Annette M Molinaro; Mitchel S Berger; Shawn L Hervey-Jumper
Journal:  Neurosurgery       Date:  2022-01-01       Impact factor: 5.315

3.  Spatial Dissection of Invasive Front from Tumor Mass Enables Discovery of Novel microRNA Drivers of Glioblastoma Invasion.

Authors:  Yulun Huang; Lin Qi; Mari Kogiso; Yuchen Du; Frank K Braun; Huiyuan Zhang; L Frank Huang; Sophie Xiao; Wan-Yee Teo; Holly Lindsay; Sibo Zhao; Patricia Baxter; Jack M F Su; Adekunle Adesina; Jianhua Yang; Sebastian Brabetz; Marcel Kool; Stefan M Pfister; Murali Chintagumpala; Laszlo Perlaky; Zhong Wang; Youxin Zhou; Tsz-Kwong Man; Xiao-Nan Li
Journal:  Adv Sci (Weinh)       Date:  2021-11-01       Impact factor: 16.806

4.  T2/FLAIR Abnormity Could be the Sign of Glioblastoma Dissemination.

Authors:  Mingxiao Li; Wei Huang; Hongyan Chen; Haihui Jiang; Chuanwei Yang; Shaoping Shen; Yong Cui; Gehong Dong; Xiaohui Ren; Song Lin
Journal:  Front Neurol       Date:  2022-02-02       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.